Subtitle: The Anal Cancer Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Anal Cancer Therapeutics Market: Drivers and Challenges
The statistics for anal cancer suggest that annually there about 6000 cases of anal cancer diagnosed in the U.S. and the number is increasing slowly. The major factors that drive the market for anal cancer therapeutics are aging population, sexually transmitted disease, multiple sexual partners and smoking. According to the World Health Organization 290 million women are suffering from HPV infection and due to unhealthy sex, the chances get doubled. For treating this anal cancer, early diagnosis is crucial which is only available in the developed countries or high-income countries and are accessible. Whereas in the low-income countries the diagnosis and treatment facilities are either costly or inaccessible. These factors are responsible for holding back the anal cancer therapeutics market and should be well tracked for future advancements.
Altogether 80% of anal cancers are developed after the age of 60 and the ones which occur prior to age 35 are mostly observed in men. Almost half of the anal caners are diagnosed before the cancer turns to be malignant but when the cancer is found through early diagnosis are treatable. The survival rate of anal cancer in male is 60% and 70% in female for 5 years. Most of the anal cancers are treated with combination therapy and some are treated with surgery when early diagnosed. Cancer treatment includes chemotherapy, radiation therapy and surgery which is also dependent on the stage of the tumor.
Anal Cancer Therapeutics Market: Regional Overview
Worldwide there are 1 or 2 cases per 100000 cases and accounts for about 1.5 % of the cases in the United States. Anal cancer therapeutics market share is more in North America followed by Europe. In U.K the incidence cases did not grow in the past few years and thus the anal cancer accounts for less than 1% of all the deaths. In the developed countries and developing countries several epidemiologic studies have found out that the chances for developing anal cancer can be directly related to sexual practices. Also the number of the sexually transmitted diseases has increased over the past couple of years leading to rise in the number of diseases and infections. The developed countries have proper healthcare facilities and thus treatment for anal cancer is possible.
Anal Cancer Therapeutics Market: Key Players
The major market players in the anal cancer therapeutics are GlaxoSmithKline Pharmaceuticals Ltd., Spectrum Pharmaceuticals, Inc., Hospira, Inc., Global BioPharma, Inc., and Advaxis, Inc.
Browse Full Report summary and to request sample report and table of content@ http://www.persistencemarketresearch.com/market-research/anal-cancer-therapeutics-market.asp
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353